Advertisement
UK markets open in 2 hours 37 minutes
  • NIKKEI 225

    37,713.02
    -747.06 (-1.94%)
     
  • HANG SENG

    17,295.93
    +94.66 (+0.55%)
     
  • CRUDE OIL

    82.87
    +0.06 (+0.07%)
     
  • GOLD FUTURES

    2,326.10
    -12.30 (-0.53%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,471.28
    -2,032.13 (-3.80%)
     
  • CMC Crypto 200

    1,388.24
    -35.86 (-2.52%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

European shares edge lower in choppy trading, drugmakers up

* FTSEurofirst index edges lower by midday

* Healthcare stocks top gainers for a second day

* Daimler (LSE: 0NXX.L - news) , Skanska (LSE: 0HBT.L - news) , Pearson (Xetra: 858266 - news) go ex-dividend (ADVISORY- Reuters plans to replace intra-day European and UK stock market reports with a Live Markets blog on Eikon (see cpurl://apps.cp./cms/?pageId=livemarkets for site in development) (Adds details)

By Danilo Masoni

MILAN, April 7 (Reuters) - European equities edged lower by midday on Thursday, as gains in healthcare shares were eclipsed by some weaker stocks such as Daimler that traded without the attraction of their latest dividend payouts.

ADVERTISEMENT

German carmaker Daimler fell more than 4 percent as its shares went ex-dividend. Among other companies losing the right to the next payout were Skanska, which fell 7 percent, making the stock the biggest faller on the FTSEurofirst, and Pearson, which slipped 5 percent.

The pan-European FTSEurofirst 300 was down 0.27 percent by 1100 GMT, with investors reluctant to place strong bets. It (Other OTC: ITGL - news) was on track for its fourth straight week of losses.

"What markets really would need are more positive global economic data ... indicating a pick-up in economic activity, especially in the Eurozone and the U.S (Other OTC: UBGXF - news) .," City of London Markets trader Markus Huber said.

European Central Bank President Mario Draghi said in the central bank's annual report on Thursday that the future of the global economy remained uncertain and there were questions about Europe's ability to weather new shocks.

Healthcare stocks were the top gainers for a second session, with the sector index rising 0.9 percent after the termination of the Pfizer (NYSE: PFE - news) -Allergan (NYSE: AGN - news) merger deal fueled talk of other consolidation activity in the sector.

Shire (Xetra: S7E.DE - news) rose 1 percent after saying it expected its deal to buy American drugmaker Baxalta (Berlin: 9BX.BE - news) to proceed as expected, while elsewhere in the sector Roche also gained 1 percent and Astrazeneca (NYSE: AZN - news) advanced 1.4 percent.

Shares (Berlin: DI6.BE - news) in STMicroelectronics (LSE: 0INB.L - news) gained 5.5 percent, the top gainer in the STOXX Europe 600 index, with some brokers linking the surge to the strong earnings update from its client Samsung, with the South Korean group flagging a 10 percent jump in quarterly profit.

The European technology index, up 0.3 percent, was the second-biggest sectoral gainer, with chipmakers ARM Holdings (LSE: ARM.L - news) and ASML Holding (LSE: 0QB8.L - news) gaining 1.9 percent and 1.4 percent respectively.

Wirecard (LSE: 0O8X.L - news) rose 1 percent after the German payments processor reported a rise in full-year profit and proposed lifting its dividend.

Today's European research round-up:

ADVISORY- Reuters plans to replace intra-day European and UK stock market reports with a Live Markets blog on Eikon (see cpurl://apps.cp./cms/?pageId=livemarkets for site in development). In a real-time, multimedia format from 0600 London time through the 1630 closing bell, it will include the best of our market reporting, Stocks Buzz service, Eikon graphics, Reuters pictures, eye-catching research and market zeitgeist. Breaking news and dramatic market moves will continue to be alerted to all clients and we will continue to provide a short opening story and comprehensive closing reports.

If you have any thoughts, suggestions or feedback on this, please email mike.dolan@thomsonreuters.com.

Mike Dolan, Markets Editor, EMEA.

(Additional reporting by Atul Prakash in London; Editing by David Holmes)